Memphasys Completes Data Lock for Felix™ Clinical Trial, Eyes CE Mark Approval

Memphasys Ltd ( (AU:MEM) ) has shared an update.

Memphasys Limited has successfully completed the data lock for its pivotal Felix™ clinical trial, marking a significant milestone in ensuring the trial’s data accuracy and integrity. This achievement prepares the company for statistical analysis and submission for CE Mark approval, pivotal for entering the European market, with plans to expand to Australia and India following approval. The preliminary trial results, expected in March 2025, are a crucial step toward the commercialization of the Felix™ System, which shows promise in reproductive biotechnology.

More about Memphasys Ltd

Memphasys Limited (ASX: MEM) specializes in reproductive biotechnology for high-value commercial applications. Their products under development include medical devices, in vitro diagnostics, and proprietary media, with a focus on their patented bio separation technology used in the Felix™ System, which combines electrophoresis with size exclusion membranes to select the most viable sperm cells for human artificial reproduction.

Average Trading Volume: 10,181,599

Technical Sentiment Consensus Rating: Strong Buy

Current Market Cap: A$10.63M

See more insights into MEM stock on TipRanks’ Stock Analysis page.